MDSpire - Summary
Commentary & Perspectives

Could Mass Spec Overcome the CAR T Solid Tumor Barrier?

Joey Sheff explains how proteomics is revealing targets, guiding CAR design, and predicting function in solid tumors.

  • April 1, 2026

  • 8 min

Share

CAR T cell therapy has transformed treatment for blood cancers, yet its application to solid tumors faces significant challenges, including elusive targets and an immunosuppressive environment. Joey Sheff from the National Research Council Canada highlights the essential role of analytical science, particularly mass spectrometry and proteomics, in enhancing CAR T therapy development. By better understanding CAR function and tumor biology, analytics can aid in the design of more effective therapies, paving the way for broader applications in cancer and beyond.

Original Source(s)

Could Mass Spec Overcome the CAR T Solid Tumor Barrier?

  • April 1, 2026

Related Content

Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers

“For women with low-risk DCIS, these interim results are reassuring. There is currently no indication that active surveillance leads to worse early outcomes compared with immediate surgery. It’s impor...

From One Stem Cell to Millions of Cancer Killers

A three-step engineering strategy generates vast numbers of potent NK immune cells – potentially slashing the cost and scaling of cancer immunotherapy

  • April 1, 2026

  • 1 min
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...